1,2,3,4-tetrahydroisoquinoline-2-carboximidamide

• ChemBase ID: 4384
• Molecular Formular: C10H13N3
• Molecular Mass: 175.23032
• Monoisotopic Mass: 175.11094743
• SMILES: N1(CCc2c(C1)cccc2)C(=N)N
• Canonical SMILES: NC(=N)N1CCc2c(C1)cccc2
• InChI: InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
• InChIKey: JWPGJSVJDAJRLW-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1,2,3,4-tetrahydroisoquinoline-2-carboximidamide
• IUPAC Traditional name: debrisoquin
• Brand Name: Declinax; Equitonil; Tendor
• Synonyms: 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide Hemisulfate; Debrisoquine Hemisulfate; Isocaramidine Hemisulfate; Debrisoquin Hemisulfate; Debrisoquine; Debrisochinum; Debrisoquin hemisulfate; Debrisoquin sulfate; Debrisoquina [inn-spanish]; Debrisoquine; Debrisoquine sulfate; Debrisoquinum [inn-latin]; Isocaramidine; Isocaramidine sulfate; Debrisoquin

Database IDs

• CAS Number: 581-88-4; 1131-64-2
• PubChem SID: 46507664; 160967816
• PubChem CID: 2966
• CHEBI ID: 34665
• ATC CODE: C02CC04
• CHEMBL: 169901
• Chemspider ID: 2860
• DrugBank ID: DB04840
• KEGG ID: C13650
• MeSH Name: Debrisoquine
• Unique Ingredient Identifier: X31CDK040E
• Wikipedia Title: Debrisoquine

CALCULATED PROPERTIES

JChem

• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): -1.348339
• LogD (pH = 7.4): -1.347392
• Log P: 1.067108
• Molar Refractivity: 63.8503 cm^3
• Polarizability: 19.882635 Å^3
• Polar Surface Area: 53.11 Å^2
• Rotatable Bonds: 0
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 0.58
• LOG S: -2.32
• Solubility (Water): 8.42e-01 g/l

PROPERTIES

Physical Property

• Solubility: Water
• Apperance: Crystalline Solid
• Hydrophobicity(logP): 0.75 [SANGSTER (1994)]

Safety Information

• Storage Condition: -20°C Freezer

DETAILS

DrugBank - DB04840

• Drug Groups: approved
• Description: An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. [PubChem]
• Indication: For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
• Pharmacology: Debrisoquin is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic.

Toronto Research Chemicals - D208700

Antihypertensive.

REFERENCES

• Abrams, et al.: J. New Drugs, 4, 268 (1964)
• Medina, et al.: Biochem. Pharmacol., 18, 891 (1964)
• Goldenthal, E.I., Toxicol. Appl. Pharmacol., 18, 185 (1964)